Publications by authors named "Visnja Fink"

Claim this Profile
C
Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?
Stefan Lukac, Kerstin Pfister, Henning Schäffler, Elena Leinert, Angelina Fink, Visnja Fink

Geburtshilfe Frauenheilkd· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?
Stefan Lukac, Kerstin Pfister, Henning Schäffler, Elena Leinert, Angelina Fink, Visnja Fink

Geburtshilfe Frauenheilkd· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer.
Stefan Lukac, Visnja Fink, Davut Dayan, Brigitte Rack, Wolfgang Janni

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?
Stefan Lukac, Visnja Fink, Thomas W P Friedl, Franziska Mergel, Kerstin Pfister

Breast Care (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eco-logistical comparison of non-radioactive seeds and the wire-guided localization for intraoperative detection of breast lesions.
Stefan Lukac, Elena Leinert, Thorsten Kühn, Davut Dayan, Florian Ebner, Visnja Fink

Eur J Surg Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ChatGPT, Google, or PINK? Who Provides the Most Reliable Information on Side Effects of Systemic Therapy for Early Breast Cancer?
Stefan Lukac, Sebastian Griewing, Elena Leinert, Davut Dayan, Benedikt Heitmeir, Visnja Fink

Clin Pract· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac health in breast cancer (CHiB): protocol for a single-centre, randomised controlled trial.
Hannes Colditz, Lynn Matits, Johannes Kersten, Sebastian Viktor Waldemar Schulz, Dominik Buckert, Visnja Fink

BMJ Open Sport Exerc Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.
Henning Schäffler, Dorothee Jakob, Sophia Huesmann, Kerstin Pfister, Kristina Veselinovic, Visnja Fink

Geburtshilfe Frauenheilkd· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients.
Johannes Kersten, Visnja Fink, Maria Kersten, Lisa May, Samuel Nunn

Int J Cardiovasc Imaging· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
Elena Leinert, Stefan Lukac, Lukas Schwentner, Antonia Coenen, Visnja Fink

Surg Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating ChatGPT as an adjunct for the multidisciplinary tumor board decision-making in primary breast cancer cases.
Stefan Lukac, Davut Dayan, Visnja Fink, Elena Leinert, Andreas Hartkopf

Arch Gynecol Obstet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Davut Dayan, Stefan Lukac, Brigitte Rack, Florian Ebner, Visnja Fink

Breast Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
Henning Schäffler, Franziska Mergel, Kerstin Pfister, Stephan Lukac, Angelina Fink, Visnja Fink

Int J Mol Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients.
Marie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, Sabine Schütze, Arkadius Polasik, Visnja Fink

Clin Breast Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.
Dominik Dannehl, Tobias Engler, Léa Louise Volmer, Christian Martin Tegeler, Julia Fusshoeller, Visnja Fink

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
Isabelle Grootes, Renske Keeman, Fiona M Blows, Roger L Milne, Graham G Giles, Visnja Fink

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Elena Leinert, Lukas Schwentner, Wolfgang Janni, Achim Wöckel, Saskia-L Herbert, Visnja Fink

Breast Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients.
Hanna Huebner, Lothar Häberle, Volkmar Müller, Iris Schrader, Ralf Lorenz, Visnja Fink

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Intermediate Results of a Prospective Multicenter Study Investigating the use of Smooth, Semi-Smooth, Microtextured and Macrotextured Implants from a Single Manufacturer in Breast Augmentation and Reconstruction Procedures.
Alexandre Marchac, Robert El Haddad, Corinne Boedec, Christian DE Greef, Fabrice Dubrulle, Visnja Fink

J Plast Reconstr Aesthet Surg· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Thomas W P Friedl, Tanja Fehm, Volkmar Müller, Werner Lichtenegger, Jens Blohmer, Visnja Fink

JAMA Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial.
Inga Bekes, Martin Eichler, Susanne Singer, Thomas W P Friedl, Nadia Harbeck, Visnja Fink

Clin Breast Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Amelie de Gregorio, Lothar Häberle, Peter A Fasching, Volkmar Müller, Iris Schrader, Visnja Fink

Breast Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Daniel Herr, Manfred Wischnewsky, Ralf Joukhadar, Olivia Chow, Wolfgang Janni, Visnja Fink

PLoS One· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer.
Kathryn J Ruddy, Daniel J Schaid, Ann H Partridge, Nicholas B Larson, Anthony Batzler, Visnja Fink

Fertil Steril· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
Rafael J A Cámara, Lukas Schwentner, Thomas W P Friedl, Miriam Deniz, Visnja Fink

Breast Cancer Res Treat· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis